The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Molecular Self-Assembly of Bioorthogonal Aptamer-Prodrug Conjugate Micelles for Hydrogen Peroxide and pH-Independent Cancer Chemodynamic Therapy
Abstract
Chemodynamic therapy (CDT) has demonstrated new possibilities for selective and logical cancer intervention by specific manipulation of dysregulated tumorous free radical homeostasis. Current CDT methods largely rely on conversion of endogenous hydrogen peroxide (H 2 O 2 ) into highly toxic hydroxyl radicals via classical Fenton or Haber–Weiss chemistry. However, their anticancer efficacies are greatly limited by the requirement of strong acidity for efficient chemical reactions, insufficient tumorous H 2 O 2, and upregulated antioxidant defense to counteract free radical-caused oxidative damage. Here, we present a new concept whereby bioorthogonal chemistry and prodrug are combined to create a new type of aptamer drug conjugate (ApDC): aptamer-prodrug conjugate (ApPdC) micelle for improved and cancer-targeted CDT. The hydrophobic prodrug bases can not only promote self-assembly of aptamers but also act as free radical generators via bioorthogonal chemistry. In depth mechanistic studies reveal that, unlike traditional CDT systems, ApPdC micelles enable in situ activation and self-cycling generation of toxic C-centered free radicals in cancer cells through cascading bioorthogonal reactions, with no dependence on either H 2 O 2 or pH, yet concurrently with diminished cancerous antioxidation by GSH depletion for a synergistic CDT effect. We expect this work to provide new insights into the design of targeted cancer therapies and studies of free radical-related molecular mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Fridovich (1978) · doi:10.1126/science.210504 · Cited by 3,329
Role of reactive oxygen species (ROS) in apoptosis induction
Simon, H.-U., Haj-Yehia, A., & Levi-Schaffer, F. (2000) · Apoptosis · doi:10.1023/a:1009616228304 · Cited by 2,774
H 2 O 2 , a Necessary Evil for Cell Signaling
Rhee, S. G. (2006) · Science · doi:10.1126/science.1130481 · Cited by 2,160
Vyas, S., Zaganjor, E., & Haigis, M. C. (2016) · Cell · doi:10.1016/j.cell.2016.07.002 · Cited by 1,735
Hussain, S. P., Hofseth, L. J., & Harris, C. C. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1046 · Cited by 1,690
Reactive oxygen species in cancer cells: Live by the sword, die by the sword
Schumacker, P. T. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.015 · Cited by 1,242
Glutathione in Cancer Biology and Therapy
Estrela, J. M., Ortega, A., & Obrador, E. (2006) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360500523878 · Cited by 1,041
Cited by
Biomedicine Meets Fenton Chemistry
Tang, Z., Zhao, P., Wang, H., Liu, Y., & Bu, W. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00977 · Cited by 745
Self-citationRecent progress of chemodynamic therapy-induced combination cancer therapy
Wang, X., Zhong, X., Liu, Z., & Cheng, L. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100946 · Cited by 711
Chemodynamic Therapy via Fenton and Fenton‐Like Nanomaterials: Strategies and Recent Advances
Jia, C., Guo, Y., & Wu, F. (2022) · Small · doi:10.1002/smll.202103868 · Cited by 685
Zhou, Y., Fan, S., Feng, L., Huang, X., & Chen, X. (2021) · Advanced Materials · doi:10.1002/adma.202104223 · Cited by 463
Glutathione-Depleting Nanomedicines for Synergistic Cancer Therapy
Cheng, X., Xu, H.-D., Ran, H.-H., Liang, G., & Wu, F.-G. (2021) · ACS Nano · doi:10.1021/acsnano.1c00498 · Cited by 374
Metadata
- Authors
- Xuan, W., Xia, Y., Li, T., Wang, L., Liu, Y., & Tan, W.
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-12-20
- Volume
- 142
- Issue
- 2
- Pages
- 937-944
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- OpenAlex
- W2995502256
- Cited by
- 240
- References
- 8
- FWCI
- 10.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.